H.C.
JMP analysts have profiled two biopharmaceutical firms that they believe are set up to do well in the rest of 2018 and beyond. Both companies are …
Evercore ISI: Teva throws lawsuit at competitor Lilly; Guggenheim: OCUL’s assets looking at $$$ billions.